Gilead Sciences has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19 infection.
The Japanese approval is supported by results from the US National Institute of Allergy and Infectious Diseases (NIAID)’s global Phase III trial and Gilead’s Phase III SIMPLE trial in patients with severe Covid-19 manifestations.
Go deeper with GlobalData
